Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The graft-versus-leukemia effect

D Mavroudis1, J Barrett

  • 1Bone Marrow Transplant Unit, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Current Opinion in Hematology
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.

ESMO open·2022
Same author

Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333-1340.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update.

Case reports in oncological medicine·2019
Same author

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.

Cancer chemotherapy and pharmacology·2018
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

The graft-versus-leukemia (GVL) effect, crucial in bone marrow transplants, can powerfully combat leukemia independently of graft-versus-host disease (GVHD). Research focuses on harnessing T lymphocytes to enhance GVL while minimizing GVHD.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • The graft-versus-leukemia (GVL) effect, long predicted, is now recognized as a significant factor in bone marrow transplantation (BMT).
  • Initially viewed as secondary to graft-versus-host disease (GVHD), recent clinical data suggest GVL can be potent and somewhat independent of GVHD.
  • Donor lymphocyte infusions (DLIs) for relapsed leukemia highlight GVL's efficacy and variability.

Purpose of the Study:

  • To define the role of the GVL effect in clinical BMT.
  • To explore strategies for enhancing GVL efficacy and separating it from GVHD.
  • To identify the cellular mediators of the GVL effect.

Main Methods:

  • Analysis of clinical BMT outcomes.
  • Evaluation of donor lymphocyte transfusions (DLTs) for relapsed leukemia.

Related Experiment Videos

  • Investigation of lymphocyte subsets (T cells, NK cells) and cytokines involved in GVL.

    • Main Results:

    • GVL effect is a powerful anti-leukemia response, potentially independent of GVHD.
    • DLTs show variable responses based on leukemia type and adjunct therapies.
    • T lymphocytes (CD4+ and CD8+ cells) and their cytokines are key mediators of GVL.
    • Leukemia cells may present distinct antigens, offering a basis for GVL/GVHD separation.

    Conclusions:

    • The GVL effect is a critical therapeutic component in BMT for leukemia.
    • Optimizing GVL requires understanding its mediators and potential for separation from GVHD.
    • Future strategies aim to enhance GVL while mitigating the risks of GVHD.